|Bid||1,598.40 x 0|
|Ask||1,658.00 x 0|
|Day's range||1,620.80 - 1,653.80|
|52-week range||1,190.80 - 1,737.00|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||19.31|
|Earnings date||09 Feb 2022|
|Forward dividend & yield||0.80 (5.04%)|
|Ex-dividend date||18 Nov 2021|
|1y target est||1,651.80|
Unilever plans to cut 1,500 management jobs as part of a major overhaul following its failed £50bn bid for GlaxoSmithKline's healthcare division.
Here are key developments around Unilever in the past two months. Unilever agreed to sell its global tea business to CVC Capital Partners for 4.5 billion euros ($5.1 billion), concluding a process of reviewing and spinning off the division that took more than two years. Unilever confirmed it had approached GlaxoSmithKline about buying its consumer goods business following media reports.
Unilever will reduce staff numbers in more than 100 countries in a bid to shore up its finances and take on a more competitive operating model.